I bet no one will followup to see if this works for other strokes, unless YOU have the money and know researchers that can run the research. No one in stroke listens to me, I have never been contacted by any stroke doctors, researchers or stroke associations. Probably because stroke is treatable according to this meme from World Stroke Day a few years ago. 9 million stroke survivors a year would disagree(10 million a year less the 10% full recovery rate.)
 |
| What a bald faced lie |
Lacunar stroke or lacunar infarct (LACI) is the most common type of ischaemic stroke, and results from the occlusion of small penetrating arteries that provide blood to the brain's deep structures.
Negative indication of using isosorbide mononitrate here;
Neurology
April 25, 2019
Cilostazol
and isosorbide mononitrate (ISMN) are well-tolerated and dose
escalation is feasible in patients with lacunar stroke, according to a
study published in EClinicalMedicine.
“We are delighted that the results of this trial show promise for treating a common cause of stroke and the [most common] cause of vascular dementia, since currently there are no effective treatments,” said Joanna Wardlaw, MD, University of Edinburgh, Edinburgh, Scotland.
For the LACunar Intervention-1 (LACI-1) study, Gordon W. Blair, University of Edinburgh, and colleagues enrolled 57 patients (32% female, median age 66 years) with clinically confirmed lacunar ischaemic stroke without cognitive impairment. Patients were randomised 1:1:1 to receive masked ISMN 25 mg twice daily, cilostazol 100 mg twice daily, both ISMN and cilostazol started immediately, or both with start delayed. Doses were escalated to target over 2 weeks, and sustained for 8 weeks.
The study found that both drugs affected systemic haemodynamic function, and may improve vasoreactivity in white matter, reduce white matter lesions, and improve cognitive performance.
Most patients achieved full (64%) or over half (87%) dose, with no difference between cilostazol versus ISMN or single versus dual drugs.
Headache and palpitations increased initially then declined similarly with dual versus single drugs.
There was no between-group differences in blood pressure, pulse-wave velocity, haemoglobin, or platelet function, but pulse rate and platelet count were higher and white matter hyperintensities reduced more with cilostazol versus no cilostazol.
The findings pave the way for larger studies to check if the treatments can prevent brain damage and reduce the risk of stroke and vascular dementia, the researchers said.
“There has not been a new drug for dementia for 15 years, so finding evidence that these cheap existing drugs could prevent dementia after a stroke would be a huge breakthrough,” concluded James Pickett, PhD, Alzheimer’s Society, London, United Kingdom. “It is promising to see that these 2 drugs are safe to use and we will be excited to see the results of the next stage of testing in a couple of years, which will show whether these drugs can be an effective treatment.”
Reference: https://doi.org/10.1016/j.eclinm.2019.04.001
SOURCE: University of Edinburgh
“We are delighted that the results of this trial show promise for treating a common cause of stroke and the [most common] cause of vascular dementia, since currently there are no effective treatments,” said Joanna Wardlaw, MD, University of Edinburgh, Edinburgh, Scotland.
For the LACunar Intervention-1 (LACI-1) study, Gordon W. Blair, University of Edinburgh, and colleagues enrolled 57 patients (32% female, median age 66 years) with clinically confirmed lacunar ischaemic stroke without cognitive impairment. Patients were randomised 1:1:1 to receive masked ISMN 25 mg twice daily, cilostazol 100 mg twice daily, both ISMN and cilostazol started immediately, or both with start delayed. Doses were escalated to target over 2 weeks, and sustained for 8 weeks.
The study found that both drugs affected systemic haemodynamic function, and may improve vasoreactivity in white matter, reduce white matter lesions, and improve cognitive performance.
Most patients achieved full (64%) or over half (87%) dose, with no difference between cilostazol versus ISMN or single versus dual drugs.
Headache and palpitations increased initially then declined similarly with dual versus single drugs.
There was no between-group differences in blood pressure, pulse-wave velocity, haemoglobin, or platelet function, but pulse rate and platelet count were higher and white matter hyperintensities reduced more with cilostazol versus no cilostazol.
The findings pave the way for larger studies to check if the treatments can prevent brain damage and reduce the risk of stroke and vascular dementia, the researchers said.
“There has not been a new drug for dementia for 15 years, so finding evidence that these cheap existing drugs could prevent dementia after a stroke would be a huge breakthrough,” concluded James Pickett, PhD, Alzheimer’s Society, London, United Kingdom. “It is promising to see that these 2 drugs are safe to use and we will be excited to see the results of the next stage of testing in a couple of years, which will show whether these drugs can be an effective treatment.”
Reference: https://doi.org/10.1016/j.eclinm.2019.04.001
SOURCE: University of Edinburgh
No comments:
Post a Comment